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Several evidences indicate that the ubiquitous nucleoside adenosine, acting through
A1, A2A, A2B, and A3 receptor (AR) subtypes, plays crucial roles in tumor development.
Adenosine has contrasting effects on cell proliferation depending on the engagement
of different receptor subtypes in various tumors. The involvement of A2AARs
in human A375 melanoma, as well as in human A549 lung and rat MRMT1
breast carcinoma proliferation has been evaluated in view of the availability of a
novel A2AAR antagonist, with high affinity and selectivity, named as 2-(2-furanyl)-
N5-(2-methoxybenzyl)[1,3]thiazolo[5,4-d]pyrimidine-5,7-diammine (TP455). Specifically,
the signaling pathways triggered in the cancer cells of different origin and the
antagonist effect of TP455 were investigated. The A2AAR protein expression was
evaluated through receptor binding assays. Furthermore, the effect of A2AAR
activation on cell proliferation at 24, 48 and 72 hours was studied. The selective
A2AAR agonist 2-p-(2-carboxyethyl)phenethylamino-5′-N-ethylcarboxamidoadenosine
hydrochloride (CGS21680), concentration-dependently induced cell proliferation in
A375, A549, and MRMT1 cancer cells and the effect was potently antagonized by the
A2AAR antagonist TP455, as well as by the reference A2AAR blocker 4-(2-[7-amino-2-
(2-furyl)[1,2,4]triazolo[2,3-a][1,3,5]triazin-5-ylamino]ethyl)phenol (ZM241385). As for the
signaling pathway recruited in this response we demonstrated that, by using the specific
inhibitors of signal transduction pathways, the effect of A2AAR stimulation was induced
through phospholipase C (PLC) and protein kinase C-delta (PKC-δ). In addition, we
evaluated, through the AlphaScreen SureFire phospho(p) protein assay, the kinases
enrolled by A2AAR to stimulate cell proliferation and we found the involvement of protein
kinase B (AKT), extracellular regulated kinases (ERK1/2), and c-Jun N-terminal kinases
(JNKs). Indeed, we demonstrated that the CGS21680 stimulatory effect on kinases
was strongly reduced in the presence of the new potent compound TP455, as well
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as by ZM241385, confirming the role of the A2AAR. In conclusion, the A2AAR activation
stimulates proliferation of A375, A549, and MRMT1 cancer cells and importantly TP455
reveals its capability to counteract this effect, suggesting selective A2AAR antagonists
as potential new therapeutics.
Keywords: A2A adenosine receptor, cancer cell proliferation, intracellular signaling pathways, Drug Discovery
and Therapy, receptor antagonist
INTRODUCTION
Adenosine, a ubiquitous purine nucleoside, is considered as
an important modulator of tissue function, increasing its
concentrations under adverse metabolic conditions. Adenosine
is produced in the extracellular space through ATP degradation
operated by specific ectoenzymes, named apyrase (CD39) and 5′-
nucleotidase (CD73) and exerts its effects by recruitment of four
G-protein-coupled A1, A2A, A2B, and A3 adenosine receptors
(ARs) (Borea et al., 2016). A1AR activation by interacting
with Gi/Go proteins inhibits adenylyl cyclase (AC), regulates
calcium and potassium channels, as well as phospholipase C
(PLC). The A2AAR couples to Gs/Golf proteins to activate AC
thus increasing cAMP levels. The A2B receptor, by recruiting
Gs/Gq protein raises AC and activates PLC. Finally, the A3AR
interacts with Gi and Gq proteins inhibiting AC and stimulating
PLC, respectively (Fredholm et al., 2011). In addition, in a
cell type specific way, all adenosine receptors may also be
linked to mitogen-activated protein kinases (MAPK), including
extracellular signal-regulated kinase (ERK) 1/2, c-Jun-N-terminal
kinase 1/2 (JNK1/2), and p38 MAPK kinase, crucial in the
modulation of cell growth and death (Schulte and Fredholm,
2000). Indeed, an important role of adenosine in human
cancerogenesis has been evidenced, as it regulates almost all the
phases of cancer development including immunoescaping, cell
proliferation, angiogenesis and metastasis, by recruiting different
adenosine receptor subtypes (Antonioli et al., 2013a,b; Borea
et al., 2017).
It is well established the relevance of immune cells in the
fight against tumors and adenosine, that increases in hypoxic
solid tumors, decreases the recognition of cancer cells by cytolytic
T cells (Blay et al., 1997; Merighi et al., 2003; Muller-Haegele
et al., 2014). Specifically, these cells are depressed by A2AARs
with the final result of an increase in hypoxic tumor cell survival
and immunoescaping as demonstrated in A2AAR gene-deficient
mice, having a much stronger antitumor immunity, rejection of
established tumors and prolonged animal survival (Ohta et al.,
2006; Sitkovsky et al., 2008; Young et al., 2016). Furthermore,
A2AARs promote wound healing and angiogenesis and are able
to increase also melanoma and breast cancer cell proliferation
(Merighi et al., 2002; Etique et al., 2009; Koszałka et al., 2016;
Perez-Aso et al., 2016). All these data support the importance of
A2AAR antagonists to combat tumor development.
Recently, a series of novel blockers, having the thiazolo[5,4-
d]pyrimidine nucleus, showing an unprecedented high affinity
for the A2AAR and a behavior as antagonists and/or inverse
agonists has been developed (Varano et al., 2016). With
the availability of the novel compound 2-(2-furanyl)-N5-(2-
methoxybenzyl)[1,3]thiazolo[5,4-d]pyrimidine-5,7-diammine
FIGURE 1 | Chemical structure of the A2AAR antagonist/inverse agonist
TP455 (2-(2-furanyl)-N5-(2-methoxybenzyl)[1,3]thiazolo[5,4-d]pyrimidine-5,7-
diammine).
(TP455) (Figure 1), the involvement of A2AARs in human A375
melanoma, as well as in human A549 lung and rat MRMT1
breast carcinoma proliferation was evaluated. In addition, the
signaling pathways triggered in the cancer cells of different origin
and the antagonist effect of TP455 were investigated.
Overall our data indicate that the A2AAR activation stimulates
proliferation of A375, A549, and MRMT1 cancer cells through
ERK1/2, JNK1/2, and AKT downstream PLC and PKC-δ.
Importantly, TP455 antagonizes this effect, adding a piece of
evidence on the effects of selective A2AAR antagonists on
cancer development thus supporting their role as potential new
anticancer drugs.
MATERIALS AND METHODS
The A2AAR antagonist/inverse agonist TP455 was recently
synthesized (compound 13 in Varano et al., 2016) and the
chemical structure is shown in Figure 1. [3H]-ZM 241385 was
from PerkinElmer (Milan, Italy). 4-(2-[7-Amino-2-(2-furyl)
[1,2,4]triazolo[2,3-a][1,3,5]triazin-5-ylamino]ethyl)phenol (ZM
241385) and 8-[4-[4-(4-Chlorophenzyl)piperazide-1-sulfonyl)
phenyl]]-1-propylxanthine (PSB 603) were purchased from
Tocris, Space Import–Export (Milan, Italy). 4- (4-Fluorophenyl)-
2-(4-hydroxyphenyl)-5-(4-pyridyl)-1H-imidazole (SB202190)
was purchased by Adipogen (Florence, Italy). D-3-Deoxy-2-O-
methyl-myo-inositol 1-[(R)-2-methoxy-3-(octadecyloxy)propyl
hydrogen phosphate] (SH5) and 1,9-Pyrazoloanthrone
(SP600125) were from Enzo Life (Florence, Italy). 1-[6-
[[(17β)-3-Methoxyestra-1,3,5(10)-trien-17-yl]amino]hexyl]-1H-
pyrrole-2,5-dione (U73122) was from Cayman (Florence, Italy).
2-p-(2-Carboxyethyl)phenethylamino-5′-N-ethylcarboxamido-
adenosine hydrochloride hydrate (CGS 21680), 5′-(N-Ethyl
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FIGURE 2 | Saturation curves of [3H]-ZM 241385 binding in A375, A549, and MRMT-1 cell lines. Experiments were performed as described in Section “Materials
and Methods”. Values are the means and vertical lines SE of the mean of four separate experiments performed in triplicate. The Scatchard plots of the same data are
shown.
carboxamido)adenosine (NECA), 1-[6-[(3-Acetyl-2,4,6-trihy
droxy-5-methylphenyl)methyl]-5,7-dihydroxy-2,2-dimethyl-2H
-1-benzopyran-8-yl]-3-phenyl-2-propen-1-one (Rottlerin) and
2-(2-Furanyl)-7-[3-(4-methoxyphenyl)propyl]-7H-pyrazolo[4,
3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine (SCH 442416)
were purchased from Sigma (Milan, Italy). PKC-ε translocation
inhibitor peptide was purchased by Calbiochem (Milan, Italy).
AlphaScreen SureFire phospho(p)ERK1/2(Thr202/Tyr204),
p-AKT1/2/3 (pThr308) and p-JNK1/3 (pThr183/Tyr185) assay
kits, AlphaScreen R© cAMP and DELFIA R© Cell Proliferation kit
were from PerkinElmer (Milan, Italy). Unless otherwise noted,
all other reagents were purchased from Sigma (Milan, Italy).
Cell Culture Conditions
Tumoral cell lines A375 (human skin malignant melanoma),
A549 (adenocarcinomic human alveolar basal epithelial cells)
and rat cell line MRMT-1 (rat breast carcinoma cells) were
purchased from ATCC and were grown adherently at 37◦C in
5% CO2/95% air. A375 and A549 were maintained in DMEM
high glucose medium containing 10% fetal calf serum, penicillin
(100 U/mL) and streptomycin (100 mg/mL) and MRMT-1
were grown in RPMI 1640 medium containing 10% fetal calf
serum, penicillin (100 U/mL), streptomycin (100 mg/mL), and L-
glutamine (2 mM). Adenosine receptor agonists and antagonists
and inhibitors of kinases, were made up in dimethyl sulfoxide
solution (DMSO) and then diluted in cell culture medium (0.1
max 0.2% of DMSO). An equal amount of DMSO was used in
control cells (CTR).
Membrane Preparation
For membrane preparation the culture medium was removed.
The cells were washed with PBS and scraped off 90 mm
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TABLE 1 | Inhibition of [3H]ZM241385 binding (Ki nM) by adenosine receptor
agonists and antagonists in human A375 melanoma, A549 lung carcinoma, and
rat MRMT-1 breast carcinoma membranes.
Compounds A375 Ki (nM) A549 Ki (nM) MRMT-1 Ki (nM)
Agonists
CGS21680 15 ± 1 16 ± 2 14 ± 1
NECA 6.65 ± 0.52 12 ± 1 9.33 ± 0.95
Cl-IB-MECA 694 ± 75 710 ± 89 500 ± 64
R-PIA 725 ± 78 670 ± 75 423 ± 52
Antagonists
SCH58261 2.82 ± 0.32 3.15 ± 0.34 3.26 ± 0.43
ZM241385 2.23 ± 0.26 2.33 ± 0.24 2.47 ± 0.23
CGS15943 1.45 ± 0.18 1.66 ± 0.20 2.15 ± 0.34
TP455 0.0058 ± 0.0002 0.0053 ± 0.0003 0.0061 ± 0.0003
The data are expressed as mean ± SE.
diameter petri dishes in ice-cold hypotonic buffer (5 mM
Tris–HCl, 2 mM EDTA, pH 7.4) (Gessi et al., 2007). The
cell suspension was homogenized with Polytron and the
homogenate was spun for 10 min at 1000 g. The supernatant
was then centrifuged for 30 min at 100,000g. The membrane
pellet was resuspended in 50 mM Tris HCl buffer pH 7.4,
10 mM MgCl2. The protein concentration was determined
according to a Bio-Rad method with BSA as a standard
reference (Bradford, 1976). Then the suspension was frozen at
−80◦C.
Saturation and Competition Binding
Experiments
Saturation binding experiments on A549, A375, and MRMT-1
cell membranes were performed by using [3H]-ZM 241385 at
different concentrations (0.1–30 nM), incubated with 100 µg
of protein per assay of membrane suspension, for 1 h
at 4◦C. Competition experiments of [3H]-ZM 241385 were
performed in duplicate in test tubes containing the buffer, the
membranes and different concentrations of A2AARs agonists and
antagonists. Non-specific binding was defined as the binding
in the presence of 1 µM ZM 241385 and was <32% of
the total binding. At the end of the incubation, bound and
free radioactivity were separated by filtering, in a Brandel
cell harvester, the assay mixture through Whatman GF/B
glass-fiber filters. The filter bound radioactivity was counted
in a liquid Scintillation Counter Tri Carb Packard 2500
TR (Perkin-Elmer Life and Analytical Sciences, Boston, MA,
United States).
AlphaScreen SureFire Assays
AlphaScreen SureFire phospho(p)ERK1/2(Thr202/Tyr204),
pJNK1/3(pThr183/Tyr185), and p-AKT1/2/3 (pThr308) assay
kits (Perkin Elmer, Milan, Italy) were utilized. Upon kinase
phosphorylation and excitation at 680 nm, fluorescent signals
at 615 nm are emitted. Cells were seeded in 100 µl culture
medium into 96-well plates (30,000/well), and incubated at
37◦C for 24 h. Cells were pretreated with various inhibitors and
TP455 for 30 min. Then, receptors were maximally stimulated
using 100 nM CGS 21680 and incubated for 5 min (ERK1/2,
JNK1/2-MAPK) or 30 min (AKT) at 37◦C. After agonist
removal, lysis buffer was added, then donor and acceptor beads
linked to specific anti-p-kinase- and anti-kinase-antibodies were
dispensed, according to manufacturer instructions. Finally,
fluorescent signals were detected through an Ensight Perkin
Elmer-multimode plate reader (Perkin Elmer, Milan, Italy). Data
were normalized to fold activation above basal p-kinase levels
(=100). For inhibitor graphs, raw data were transformed into
percentages relative to controls (basal level = 100%) in order to
merge data from several experiments.
DELFIA Cell Proliferation Kit
The DELFIA assay was performed to determine cell proliferation
according to the manufacturer’s protocol from PerkinElmer
(Milan, Italy). The assay is a time-resolved fluoroimmunoassay
based on the incorporation of BrdU into newly synthesized
DNA strands of proliferating cells cultured in microliter
plates. Incorporated BrdU is detected using a europium
labeled monoclonal antibody and the fluorescence measured
is proportional to the DNA synthesis in the cell population
of each well. A375, A549, and MRMT-1 cells were cultured
over night at 1000 cells/well in a 96-well plate (at a final
volume of 100 µl per well), agonists and antagonists were
added and the cells were incubated for 30′ before addition
of the BrdU-Labeling solution 10 µl/well. The cells were then
cultured for 24, 48, or 72 h. At the end of the incubation
period, cells were fixed (fix solution 100 µl/well), added with
100 µl/well of Anti-BrdU-Eu (0.5 µg/ml) and incubated for
120 min at room temperature. After four washes, 200 µl
of DELFIA Inducer were added at room temperature for
15 min and the Eu-fluorescence was detected through an
Ensight Perkin Elmer-multimode plate reader (Perkin Elmer,
Milan, Italy). Two kinds of controls were performed: the
blank where no cells were added to the well but only culture
medium and the background where no BrdU was added to the
wells.
Statistical Analysis
For saturation binding experiments, determination of receptor
affinity (KD) and receptor density (BMAX) was performed using
the non-linear least-squares curve fitting program LIGAND
(Munson and Rodbard, 1980). LIGAND was also used to
determine inhibitory binding constant (Ki) values from the
competition binding experiments. All values in the figures and
text are expressed as mean ± standard error (SE) of three
independent experiments. Data sets were examined by one-
way analysis of variance (ANOVA) and Dunnett’s test (when
required). ∗P < 0.05 was considered significant.
RESULTS
Saturation Studies
The expression of A2AARs in A375, A549, and MRMT-1 cells
was determined performing saturation binding experiments with
[3H]-ZM 241385. The saturation curves of [3H]-ZM 241385
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FIGURE 3 | Effect of CGS 21680 on cell proliferation in A549 (A), MRMT-1 (B), and A375 (C) cell lines. Cells were incubated in the presence of 0.01–10 µM CGS
21680 for 24, 48, and 72 h and cell proliferation was evaluated by DELFIA Cell Proliferation Kit. Solutions were made up in DMSO and then diluted in cell culture
medium (0.1 max 0.2% of DMSO). An equal amount of DMSO was used in control cells (CTR). ∗P < 0.01 compared with CTR. Means ± SE values from four
experiments are shown. Analysis was by one way ANOVA, followed by Dunnett’s test.
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FIGURE 4 | Effect of 100 nM CGS 21680 on A375 and MRMT-1 cell viability (48 h) as well as in A549 (24 h) and antagonism by 100 nM ZM 241385 and 10 nM
TP455 by DELFIA Cell Proliferation Kit. Solutions were made up in DMSO and then diluted in cell culture medium (0.1 max 0.2% of DMSO). An equal amount of
DMSO was used in control cells (CTR) incubated for 24 h in case of A549 and 48 h in case of A375 and MRMT-1. ∗P < 0.01 compared with CTR. Means ± SE
values from four experiments are shown. Analysis was by one way ANOVA, followed by Dunnett’s test.
binding, reported in Figure 2, show a KD value of 2.75 ± 0.25,
2.98± 0.31 nM, 2.17± 0.18 nM, and a Bmax of 178± 20, 110± 9,
21 ± 4 fmol mg−1of protein in A375, A549, and MRMT-1 cells,
respectively. The Scatchard plots in the insert are linear failing
to show a significantly better fit to a two-site than to a one-site
binding model, demonstrating that only one class of high affinity
binding sites is present in our experimental conditions (Munson
and Rodbard, 1980).
Competition Experiments
The affinity values of the examined ligands obtained in [3H]-
ZM 241385 competition binding experiments performed in
A375, A549, and MRMT-1 cell membranes were determined,
as shown in Table 1. The order of potency of the agonists
was as follows: NECA > CGS 21680 > R-PIA = Cl-IB-
MECA. The order of potency of the antagonists was as follows:
TP455 > CGS15943 > ZM241385 > SCH58261. Specifically, the
novel compound TP455 revealed a very good affinity for rat and
human A2AARs with Ki value in the picomolar range in all the
three cell lines investigated.
Increase in Cell Proliferation Induced by
CGS 21680 in Cancer Cell Lines
The effect of A2AARs activation on tumor cell proliferation was
evaluated in A549, MRMT-1, and A375 cancer cells. Specifically,
the A2AARs selective agonist CGS21680 (10–100 nM) was
applied to cancer cells for 24, 48, and 72 h of incubation
before assessing proliferation. The results show that in A549
cells CGS 21680 slightly increased cell proliferation only when
used at the concentration of 100 nM for 24 h and its effect
was not more present after 48 and 72 h (Figure 3A). As
for MRMT-1 cells the A2AARs agonist at 10 nM raised cell
vitality after 48 and 72 h of treatment, while a significant
stimulation was observed with CGS 21680 100 nM at all
the time points investigated (Figure 3B). In A375 cells the
stimulatory effect of cell proliferation A2AARs-dependent was
revealed only at 48 h of treatment with CGS21680 100 nM
(Figure 3C).
Antagonism of CGS 21680-Induced Cell
Proliferation in Cancer Cell Lines by the
New A2AARs Selective Antagonist TP455
In order to verify that the increase of cell proliferation induced
by CGS21680 was mediated through A2AARs stimulation we
antagonized its effect by using the standard antagonist ZM
241385. MRMT-1, A375 as well as A549 cells were pretreated
for 30 min with 100 nM ZM 241385 before stimulation
with 100 nM CGS21680 for 48 h with exception of A549
tested after 24 h. As shown in Figure 4 this compound
was able to completely block the agonist effect in all the
cell lines studied, confirming the involvement of A2AARs in
cancer cell proliferation. Therefore, the ability of the new
selective and high affine A2AARs compound TP455 to revert
cell proliferation induced by CGS21680 was investigated. Our
results show that the increase in cell vitality CGS21680-
dependent was antagonized by addition of 10 nM TP455 in
all cancer cells, suggesting that this novel derivative behaves
as an A2AARs antagonist (Figure 4). When tested alone
10 nM TP455 and 100 nM ZM 241385 did not alter cell
proliferation, showing a behavior of pure A2AAR antagonists
(Figure 4).
Signaling Pathways Involved in Cell
Proliferation Induced by CGS 21680 in
Cancer Cell Lines
The involvement of PLC, AC, PKCε, and PKCδ in the increase
of cell proliferation due to A2AAR activation was investigated.
Cells were incubated with U73122 (U73), SQ22,536 (SQ),
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FIGURE 5 | Signaling pathways involved in cell proliferation induced by CGS 21680 in cancer cell lines. Effect of 100 nM CGS 21680 on A375, MRMT cell viability
(48 h) as well as in A549 (24 h) and inhibition by 10 µM U73, SQ, PKCε-I, and Rott (A), 10 µM SB202190 (SB), U0126 (U0), SP600125 (SP), and SH5 (B) by DELFIA
Cell Proliferation Kit. Solutions were made up in DMSO and then diluted in cell culture medium (0.1 max 0.2% of DMSO). An equal amount of DMSO was used in
control cells (CTR) incubated for 24 h in case of A549 and 48 h in case of A375 and MRMT-1. ∗P < 0.01 compared with CTR. Means ± SE values from four
experiments are shown. Analysis was by one way ANOVA, followed by Dunnett’s test.
PKCε-translocation inhibitor peptide (PKCε-I), and rottlerin
(Rott) as inhibitors of PLC, AC, PKCε, and PKCδ, respectively.
MRMT-1, A375 as well as A549 cells were pretreated for
30 min with 10 µM inhibitors before stimulation with
100 nM CGS21680 for 48 h with exception of A549 tested
after 24 h. All inhibitors alone did not significantly affect
cell proliferation (Figure 5A). As shown in Figure 5A
blockers of PLC and PKCδ were able to antagonize the
stimulatory effect of 100 nM CGS21680, suggesting the
involvement of these enzymes in the A2AAR agonist effect,
while inhibitors of AC and PKCε did not block the agonist
effect.
In addition, to evaluate MAPK and AKT pathways
involvement in A2AAR-mediated cell proliferation, cells
were pretreated for 30 min with 10 µM U0126, SB202190,
SP600125, and SH5, inhibitors of ERK1/2, p38, JNK1/2 MAPK
kinases and AKT, respectively, before exposure to 100 nM CGS
21680 for 48 h with exception of A549 tested after 24 h. All
inhibitors alone did not significantly affect cell proliferation
(Figure 5B). As shown in Figure 5B, U0126, SP600125,
and SH5 strongly reduced the effect of CGS21680 on cell
proliferation, whilst SB202190 did not. These results suggest
the involvement of ERK1/2, JNK1/2 MAPK kinases, and
AKT in the increase of cell proliferation mediated by A2AAR
activation.
Effect of CGS 21680 on ERK1/2, JNK
MAPK Kinase, and AKT Phosphorylation
To confirm the role of ERK1/2, JNK1/2 MAPK kinases,
and AKT in the increase of cell proliferation mediated by
A2AAR activation, kinases phosphorylation was assessed at
0–60 min in the absence and in the presence of 100 nM
CGS 21680, as stimulator of A2AARs in MRMT-1, A375
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FIGURE 6 | Effect of CGS 21680 on pERK1/2, pJNK1/2 MAPK kinase, and pAKT activation. Cells were incubated in the presence of 100 nM CGS 21680 for 0, 5,
10, 30, and 60 min and pERK1/2 (A), pJNK1/2 (B), and pAKT (C) protein levels were evaluated by AlphaScreen SureFire pMAPK assays in MRMT-1, A375, and
A549 cells. Solutions were made up in DMSO and then diluted in cell culture medium (0.1 max 0.2% of DMSO). An equal amount of DMSO was used in control cells
(CTR). ∗P < 0.01 compared with time 0. Means ± SE values from four experiments are shown. Analysis was by one-way ANOVA followed by Dunnett’s test.
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FIGURE 7 | Effect of antagonists on CGS 21680-dependent pERK1/2, pJNK MAPK kinase, and pAKT activation. MRMT-1, A375, and A549 cells in the absence or
in the presence of 100 nM ZM 241385 and 10 nM TP455 were exposed to 100 nM CGS for 5 min or for 30 min and pERK1/2 (A), pJNK (B), and pAKT (C) protein
levels were evaluated by AlphaScreen SureFire pMAPK assays respectively. Solutions were made up in DMSO and then diluted in cell culture medium (0.1 max 0.2%
of DMSO). An equal amount of DMSO was used in control cells (CTR). ∗P < 0.01 compared with CGS 21680 100 nM. Means ± SE values from four experiments
are shown. Analysis was by one-way ANOVA followed by Dunnett’s test.
and A549 cells (Figures 6A–C, respectively). ERK1/2 and
JNK1/2 phosphorylation reached a maximal effect after
5 min of A2AAR stimulation and disappeared at 60 min,
while AKT phosphorylation started to increase after 10 min
of treatment and decreased after 60 min. Furthermore,
ERK1/2, JNK, and AKT phosphorylation were higher in
MRMT-1 compared to A375 and A549 cells (Figures 6A–C,
respectively).
Antagonism of CGS 21680-Induced
ERK1/2, JNK1/2 MAPK Kinase and AKT
Phosphorylation by the New A2AARs
Selective Antagonist TP455
To evaluate whether stimulation of ERK1/2, JNK1/2, and AKT
phosphorylation CGS21680-dependent was induced through
A2AAR activation we antagonized it by using the standard
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FIGURE 8 | Effect of 100 nM CGS 21680 on pERK1/2 (A), pJNK1/2 (B), and pAKT (C) protein levels in MRMT-1, A375 and A549 cells and antagonism by 10 µM
U73122 (U73) and 10 µM rottlerin (Rott) evaluated by AlphaScreen SureFire pMAPK assays. Solutions were made up in DMSO and then diluted in cell culture
medium (0.1 max 0.2% of DMSO). An equal amount of DMSO was used in control cells (CTR). ∗P < 0.01 compared with CTR. Means ± SE values from four
experiments are shown. Analysis was by one-way ANOVA followed by Dunnett’s test.
antagonist ZM 241385. MRMT-1, A375, and A549 cells
were pretreated for 30 min with 100 nM antagonist before
stimulation with 100 nM CGS21680 for 5 (ERK1/2, JNK1/2)
or 10 min (AKT) to assess kinases phosphorylation. As
shown in Figures 7A–C the effect of CGS 21680 on ERK1/2,
JNK1/2, and AKT phosphorylation, respectively, was completely
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FIGURE 9 | A2A adenosine receptors-triggered signal transduction cascade in
cancer cells. CGS21680 agonist by activating A2AARs increases cell
proliferation through a pathway dependent on PLC, PKCδ, pERK1/2, pJNK,
and pAKT signaling. This effect is potently antagonized by the newly
synthesized derivative TP455.
reverted by ZM 241385. In addition the ability of the
A2AAR antagonist TP455 to block kinases phosphorylation
induced by CGS21680 was studied. Our results show that
this effect was potently inhibited by pre-treatment for 30 min
with 10 nM TP455 in MRMT-1, A375, and A549 cells
(Figures 7A–C).
Characterization of ERK1/2, JNK1/2
MAPK Kinase, and AKT Signaling
Cascade Triggered by CGS 21680 in
Cancer Cell Lines
Finally, in order to deeply investigate the signaling cascade
triggered by A2AAR activation in the increase of ERK1/2,
JNK1/2, and AKT phosphorylation, MRMT-1, A375, and A549
cells were incubated with PLC and PKCδ inhibitors before
the exposure to 100 nM CGS 21680. Then ERK1/2, JNK1/2,
and AKT phosphorylation status was examined. As reported
in Figure 8 phosphorylation of ERK1/2, JNK1/2, and AKT
mediated by CGS21680 was strongly reduced in the presence
of 10 µM U73 and Rott suggesting that PLC and PKCδ
were upstream of ERK1/2, JNK1/2 and AKT (Figures 8A–C,
respectively).
DISCUSSION
Several data in literature support an important role of adenosine
in tumor development. Indeed, adenosine may act as both
an anti- or pro-tumoral endogenous nucleoside depending on
which adenosine receptor subtype is recruited (Borea et al.,
2016, 2017). Specifically, as for the anti-tumoral effect, the
main receptor subtype involved results the A3AR for which
the successful data obtained in preclinical studies lead to the
development of A3AR selective agonists, now under evaluation
in clinical studies for the treatment of hepatocellular carcinoma
(Stemmer et al., 2013; Jacobson et al., 2017). Instead, as for
the protumoral effect, it is well established the enrollment of
A2AAR subtype in immune depression of anticancer response,
in angiogenesis stimulation as well as in promotion of cancer
cell migration, suggesting a role of A2AARs antagonists in
the fight against cancer (Antonioli et al., 2013a,b, 2016). In
addition, A2AARs have been suggested as regulators of cancer
cell proliferation in melanoma and breast cancer, but the
signaling pathways have not been deeply depicted (Merighi
et al., 2002; Etique et al., 2009; Mediavilla-Varela et al.,
2013).
In this study, we investigated the effect of A2AAR activation
in the modulation of cell proliferation in A375 melanoma, A549
lung and MRMT-1 breast carcinoma, the mechanisms involved
and the efficacy of a novel antagonist to counteract A2AAR effects
on cell growth.
Our results show that A2AARs are expressed in all the
three cancer cell lines investigated, with the following order of
expression: A375 > A549 > MRMT-1 as evaluated through
receptor binding experiments. In order to investigate the
role of A2AARs in cancer growth we evaluated cancer cell
proliferation, following the treatment with a selective A2AAR
agonist, and we found an increase of it, with a most significant
effect in MRMT-1 cells. The mechanism involved does not
affect AC or PKC-ε pathways but recruited PLC and PKC-δ
stimulation. In addition, cell proliferation mediated by A2AARs
was blocked by selective ERK1/2, JNK1/2, and AKT but
not p38 inhibitors. Accordingly, phosphorylation of ERK1/2,
JNK1/2, and AKT was significantly increased by A2AARs. It is
interesting to note that ERK1/2, JNK1/2, and AKT activation
by A2AARs depends on PLC and PKC- δ stimulation, as
demonstrated through the block of kinases phosphorylation
following treatment with PLC and PKC- δ inhibitors. These data
suggest that PLC and PKC- δ are upstream ERK1/2, JNK1/2,
and AKT in the signaling proliferative pathway induced by
A2AARs.
These data are in agreement with other studies where
A2AAR activation was associated to an increase in cell growth
such as A375 melanoma, MCF-7 breast and A549 lung
carcinoma (Gessi et al., 2011). Specifically, in A375 cells
the association of A2AAR mediated cell proliferation with
ERK1/2 has been already observed (Merighi et al., 2002).
However, in A549 cell line, a direct increasing apoptotic
effect, due to A2AAR antagonist treatment was observed, even
though the high concentration used in the reported study
does not exclude the possible interaction with other receptors
(Mediavilla-Varela et al., 2013). Therefore, the novelty of
this work is to depict a novel signaling cascade involving
the classical kinases ERK1/2, JNK1/2, and AKT downstream
A2AARs, PLC, and PKC- δ, linked in the tumorigenic processes
(Figure 9).
All the effects observed in this study, activated by the
A2AAR agonist, were reversed by the standard A2AAR antagonist
ZM241385, confirming the role of A2AARs in the signaling
investigated. Importantly, the behavior of the novel compound
TP455 similar to ZM241385, able to potently block A2AAR-
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induced cancer cell proliferation and kinase phosphorylation,
indicates a role for it as a novel potent A2AAR antagonist.
Interestingly, this class of compounds is already under clinical
development due to its anti-Parkinson therapeutic effects and is
well known to be safe and well tolerated (Preti et al., 2015; Jazayeri
et al., 2017).
Overall our data help to implement the knowledge concerning
the signaling of A2AARs in cancer. However, to support the
relevance of these receptors as novel targets in the therapy
against cancer and the development of potent and selective
antagonists, it will be important to evaluate whether A2AARs
are also involved in normal cell proliferation and the signaling
pathway enrolled.
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